Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
CompletedNCT03947749
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Genetic variability from epigenetic modification of genes related to pain physiology and opioid pharmacodynamics may influence susceptibility to high-impact chronic musculoskeletal pain, opioid efficacy, and vulnerability to opioid abuse. Exploring the role of epigenomics and opioid addiction may improve understanding and treatment of these complex multifactorial conditions and, potentially, reduce their development.
Study details
- Official title
- Linking Epigenomics With Prescription Opioid Abuse and High Impact Musculoskeletal Pain
- Conditions
- Pain, Chronic
- Prescription Drug Abuse (Not Dependent)
- Sponsor
- University of Florida
- Collaborators
- Florida Medical Malpractice Joint Underwriting Association
- Start date
- 2019-09-25
- Primary completion
- 2023-04-05
- Sex
- All
- Age range
- from 18 Years
- Healthy volunteers
- true
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Patients age ≥18 years with chronic musculoskeletal pain (pain present for 3 or more months) treated with prescription opioids on most days in the past 3 months. Exclusion Criteria: * Patients who are non-English speaking, * Patients who are incarcerated * Patients who are unable to provide consent will be excluded.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03947749